PAX/PPARγ fusion rearrangement has an inactivating effect on the tumour-suppressor gene PPARγ and is found in 30–60% of FTC and in 38% of the follicular variant of papillary thyroid cancer (FVPTC) [42,44]. Here, PPARG is linked to neoplasm.